

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

**(Use as many sheets as necessary)**

Sheet	1	of	3
-------	---	----	---

Application Number	
Filing Date	9-24-03
First Named Inventor	Bobrowski, Paul J.
Art Unit	
Examiner Name	
Attorney Docket Number	PHMC0745-021

[illegible][illegible]

Examiner Signature	SP McCormick-Ewaldt
--------------------	---------------------

Date Considered	5-5-05
-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	
		Filing Date	9-29-03
		First Named Inventor	Bobrowski, Paul J.
		Art Unit	
		Examiner Name	
Sheet 2	of 3	Attorney Docket Number	PHMC0745-021

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SBM		RINALDO MARINI BETTOLO & M. LUISA SCARPATI, Alkaloids of Croton Draconoides, Article, 1 page, 1979	
		GEORGIA PERSINOS PERDUE ET AL., South American Plants II: Taspine Isolation and Anti-Inflammatory Activity, J. of Pharmaceutical Sciences, V68 No.1 Jan 1979, pg. 124 U.S.	
		ABRAHAM J. VAISBERG et al., Taspine is the Cicatrizant Principle in Sangre de Grado Extracted from Croton Lechleri, Plant Medica 55 (1989), pgs 140-143, U.S.	
		LUC PIETERS ET AL., Isolation of a Dihydrobenzofuran Ligan from South American Dragon's Blood (Croton spp.) as an Inhibitor of Cell Proliferation, 1993, U.S.	
		J. DAVID PHILLIPSON, A Matter of Some Sensitivity, PhytoChemistry, Vol.38 No.6 pp1319-1343, 1995 U.S.	
		MARK J.S. MILLER ET AL., Inhibition of Neurogenic Inflammation by the Amazonian Herbal Medicine Sangre de Grado, J. Invest Dermatology 117:725-730, 2001, U.S.	
		S.E. GABRIEL ET AL., A Novel Plant-Derived Inhibitor of cAMP-mediated fluid and Chloride Secretion, Am. J. Physiol. 267, G58-63, 1999, U.S.	
		MARK HOLODNIY, M.D. ET AL., A Double Blind Randomized, Placebo-Controlled Phase II Study to Assess the Safety and Efficacy.... Am. J. Gastroenterology, Vol94, No.11, 1999, U.S.	
		BEATE ILLEK ET AL., A novel extract from the bark latex of Croton lechleri inhibits cAMP-mediated chloride secretion..., Dec. 2000, U.S.	
		MARK J.S. MILLER ET AL., Treatment of gastric ulcers and diarrhea with the Amazonian herbal medicine ..., Am J Physiol Gastrointes Liver Physiol 279: G192-200, 2000	

Examiner Signature	S.B. McCormick-Ewaldt	Date Considered	5-5-05
--------------------	-----------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	
		Filing Date	9-29-03
		First Named Inventor	Bobrowski, Paul J.
		Art Unit	
		Examiner Name	
Sheet 3	of 3	Attorney Docket Number	PHMC0745-021

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SMV		MANUEL SANDOVAL, Sangre de grado Croton palanostigma induces apoptosis in human gastrointestinal cancer cells, J. Ethno-Pharmacology, 80, pp. 121-129, 2002, U.S.	
SMV		Zheng-Ping Chen et al., Studies on the Anti-Tumour, Anti-Bacterial, and Wound-Healing Properties of Dragon's Blood, Planta Med. 60 (1994) 541-545	

Examiner Signature	S.B. McCormick - Ewald	Date Considered	5-5-05
--------------------	------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.